Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Free Report) declared an annual dividend on Wednesday, July 24th, Wall Street Journal reports. Investors of record on Friday, January 1st will be given a dividend of 0.4069 per share on Tuesday, July 30th. This represents a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, July 30th.
Dr. Reddy’s Laboratories has increased its dividend by an average of 13.1% annually over the last three years. Dr. Reddy’s Laboratories has a dividend payout ratio of 12.0% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Dr. Reddy’s Laboratories to earn $3.86 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 12.4%.
Dr. Reddy’s Laboratories Stock Performance
Shares of RDY opened at $81.22 on Monday. The firm has a market cap of $13.55 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.82 and a beta of 0.55. Dr. Reddy’s Laboratories has a 12 month low of $63.72 and a 12 month high of $81.98. The company’s fifty day moving average is $74.02 and its 200-day moving average is $73.29. The company has a quick ratio of 1.92, a current ratio of 2.58 and a debt-to-equity ratio of 0.02.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on RDY shares. Barclays raised their price target on Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, May 8th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 16th.
Check Out Our Latest Stock Analysis on RDY
About Dr. Reddy’s Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
Recommended Stories
- Five stocks we like better than Dr. Reddy’s Laboratories
- Where Do I Find 52-Week Highs and Lows?
- Verizon Stock: 4 Reasons to Buy This Bargain After Recent Dip
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why a Weaker Dollar is Good News for These 3 Stocks
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Why Bank of America Just Approved a Huge Stock Buyback Program
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.